CARBOPLATINE MEDAC 10 mg/mL clinical trials
3 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
A multicentre phase II, open-label, non-randomized study evaluating Platinum-Pemetrexed-Atezolizumab ( Bevacizumab) for patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutations, ALK rearrangement or ROS1 fusion progressing after Targeted therapies
This study looks at a new combination of existing medicines for a type of lung cancer (NSCLC) that has worsened after previous treatments. It aims to see how many patients respond positively to this new treatment approach.
For: Lung Cancer · NSCLCFrance - AuthorisedTherapeutic exploratory (Phase II)
Safety and Efficacy of Neoadjuvant immunotherapy with Durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (Gemcitabin/Cisplatin or Gemcitabin/Carboplatin) in patients with operable, high-risk, localized urothelial carcinoma of the upper urinary tract. iNDUCT - GETUG V08
This study is looking at a new combination of treatments for a type of bladder or kidney cancer which has not spread. It combines a new drug (Durvalumab) with standard chemotherapy to see if it can shrink the cancer before surgery, aiming to remove all cancer cells.
For: The patient has a histologically-confirmed (ureteroscopic biopsy) or cytologically(urine cytology)-confirmed diagnosis of high-grade urothelial carcinoma of the renal pelvis or ureter.France - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Pembrolizumab Alone versUs pembrolizumab-chemotherapy in first LInE NSCLC (PAULIEN)
This study is comparing two ways to treat advanced lung cancer (NSCLC) for the first time. We're looking at whether combining pembrolizumab with chemotherapy works better than pembrolizumab alone to shrink tumours or stop them from growing.
For: Advanced stage NSCLCNetherlands